Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 11/26/13  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Rhett M. Schiffman

Wrong Dr. Rhett M. Schiffman?

Board Director

Phone: (415) ***-****  HQ Phone
Glaucoma Research Foundation
251 Post Street Suite 600
San Francisco, California 94108
United States

Company Description: Founded in 1978 and headquartered in San Francisco, Glaucoma Research Foundation is America's oldest and most experienced institution dedicated solely to its...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • MD
    University of Juarez , Mexico
  • MS
  • BS , Bioengineering
    Columbia University , School of Engineering and Applied Sciences
  • Master's degrees , Clinical Research Design and Statistical Analysis and in Health Services Administration
    University of Michigan
  • Master's Degree , Clinical Research Design and Statistical Analysis
    University of Michigan
  • Master's Degree , Health Services Adminstration
    University of Michigan
26 Total References
Web References
Board of Directors | Glaucoma Research Foundation
www.glaucoma.org, 26 Nov 2013 [cached]
Rhett M. Schiffman, MD, MS, MHSA
Chief Medical Officer Neurotech Pharmaceuticals
Allergan VP Dr. Rhett Schiffman Joins Board of Directors | Glaucoma Research Foundation
www.glaucoma.org, 1 Aug 2010 [cached]
Allergan VP Dr. Rhett Schiffman Joins Board of Directors | Read More » Allergan VP Dr. Rhett Schiffman Joins Board of Directors | Glaucoma Research Foundation
...
Allergan VP Dr. Rhett Schiffman Joins Board of Directors email
...
San Francisco, CA, August 1, 2010 - Rhett M. Schiffman, MD, MS, MHSA, the Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan, Inc., has joined the Board of Directors of the Glaucoma Research Foundation (GRF) in San Francisco.
Dr. Schiffman joined Allergan in 2001 and has had responsibility for the development and approval of numerous ophthalmic medications including RESTASIS®, ELESTAT®, ZYMAR®, ZYMAXID™, ACULAR LS® ACUVAIL®, COMBIGAN® and LUMIGAN® 0.01%.
"Rhett's work as a clinician, researcher and teacher, along with his dedication to patient care through his work at Allergan, makes him an excellent addition to our Board," said Thomas M. Brunner, President and CEO of the Glaucoma Research Foundation.
...
Dr. Schiffman received his BS in Bioengineering from Columbia University, School of Engineering and Applied Sciences and his MD from the University of Juarez, Mexico. He also received Master's degrees in Clinical Research Design and Statistical Analysis and in Health Services Administration from the University of Michigan. He completed residencies in both Internal Medicine and Ophthalmology at Henry Ford Hospital and is Board Certified in both and also completed a Uveitis fellowship from the National Eye Institute at the National Institutes of Health.
In addition to his work for Allergan, Dr. Schiffman continues to see patients and teach residents at the University of California at Irvine where he is Associate Clinical Professor of Ophthalmology.
Executive Team & Board Of Directors | Neurotech Pharmaceuticals
www.neurotechusa.com, 10 Oct 2013 [cached]
Rhett Schiffman, M.D., M.S., M.H.SA
Chief Medical Officer
Dr. Schiffman joined Neurotech as CMO in September 2013. Rhett Schiffman was most recently Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan, where since 2001 he was instrumental in the global development and approval of many of ophthalmology's most successful products including Restasis®, Combigan®, Lumigan®, Acuvail® and Acular®, Zymaxid® and Zymar® and most recently, the Lumigan® and Ganfort® unit dose products. He also currently serves on the Board of Directors of the Glaucoma Research Foundation and is Associate Clinical Professor of Ophthalmology at the University of California at Irvine.. Dr. Schiffman received his B.S. in Bioengineering from Columbia University, School of Engineering and Applied Sciences and his M.D. from the University of Juarez, Mexico. He also received Master's degrees from the University of Michigan in Clinical Research Design and Statistical Analysis and in Health Services Administration. He completed residencies in both Internal Medicine and Ophthalmology at Henry Ford Hospital, is Board Certified in both and completed a Uveitis fellowship at the National Eye Institute at the National Institutes of Health.
Board of Directors | Glaucoma Research Foundation
www.glaucoma.com, 15 June 2013 [cached]
Rhett M. Schiffman, MD, MS, MHSA
Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology Allergan, Inc.
Rhett M. Schiffman, MD, MS, MHSA | Glaucoma Research Foundation
www.glaucoma.org, 31 Oct 2012 [cached]
Rhett M. Schiffman, MD, MS, MHSA
...
Dr. Rhett Schiffman is Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan, Inc.
Dr. Schiffman received his BS in Bioengineering from Columbia University, School of Engineering and Applied Sciences and his MD from the University of Juarez, Mexico. He completed a residency in Internal Medicine at Henry Ford Hospital and is Board Certified.
While a senior staff physician in the Department of Internal Medicine at Henry Ford Hospital, he completed a Master's Degree in Clinical Research Design and Statistical Analysis at the University of Michigan's School of Public Health. He was a staff scientist in the Center for Clinical Effectiveness and the Director of General Internal Medicine Research concentrating on decision analysis, clinical policy assessment and medical informatics.
Dr. Schiffman then completed a residency in Ophthalmology and received Board Certification. He also completed a Fellowship in Uveitis and Ocular Immunology at the National Eye Institute of the National Institutes of Health. He returned to Henry Ford Hospital as the Director of Uveitis Services and the Director of Clinical Research where he was Principal Investigator of numerous NIH and Industry funded studies and authored numerous articles and book chapters. He also received a Master's Degree in Health Services Adminstration from the University of Michigan.
Dr. Schiffman joined Allergan in 2001 and had responsibility for the approval of numerous ophthalmic medications including RESTASIS™, ELESTAT™, ZYMAR™, ZYMAXID™, ACULAR LS™, ACUVAIL™, COMBIGAN™ and LUMIGAN 0.01%™.
He continues to see patients and teach residents at the University of California at Irvine where he is Associate Clinical Professor of Ophthalmology. Dr. Schiffman joined the Glaucoma Research Foundation Board of Directors in 2010.
Other People with the name "Schiffman":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304